Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2007-02-13
2007-02-13
Berch, Mark L. (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C540S200000
Reexamination Certificate
active
10463388
ABSTRACT:
One embodiment of the invention relates to compounds of the formula I:in which R1, R2, R3, R4, R5 and R6 have the meanings given in the specification. Other embodiments of the invention relate to physiologically acceptable salts of the compounds of formula 1, to processes for their preparation and to medicaments comprising these compounds. The compounds of the invention are suitable for use, for example, as hypolipidemics.
REFERENCES:
patent: 5656624 (1997-08-01), Vaccaro et al.
patent: 5756470 (1998-05-01), Yumibe et al.
patent: 5889002 (1999-03-01), Nielsen et al.
patent: 6225310 (2001-05-01), Nielsen et al.
patent: 6268343 (2001-07-01), Knudsen et al.
patent: 6498156 (2002-12-01), Glombik et al.
patent: 6703386 (2004-03-01), Glombik et al.
patent: 2002/0039774 (2002-04-01), Kramer et al.
patent: 2002/0128252 (2002-09-01), Glombik et al.
patent: 2002/0128253 (2002-09-01), Glombik et al.
patent: 2002/0137689 (2002-09-01), Glombik et al.
patent: 2004/0067913 (2004-04-01), Jaehne et al.
patent: 2004/0077623 (2004-04-01), Jaehne et al.
patent: 2004/0082561 (2004-04-01), Jaehne et al.
patent: 100 64 398 (2002-01-01), None
patent: 101 52 981 (2003-05-01), None
patent: WO 96/19450 (1996-06-01), None
patent: WO 97/16455 (1997-05-01), None
patent: WO 97/26265 (1997-07-01), None
patent: WO 97/41097 (1997-11-01), None
patent: WO 97/45406 (1997-12-01), None
patent: WO 98/08871 (1998-03-01), None
patent: WO 99/03861 (1999-01-01), None
patent: WO 00/63703 (2000-10-01), None
patent: WO 02/18432 (2002-03-01), None
patent: WO 02/50027 (2002-06-01), None
patent: WO 02/50060 (2002-06-01), None
patent: WO 02/50068 (2002-06-01), None
patent: WO 2004005247 (2004-01-01), None
International Search Report, PCT/EP 03/05816, dated Aug. 28, 2003.
Allen R. Hilgers et al., “Caco-2 Cell Monolayers as a Model for Drug Transport Across the Intestinal Mucosa”; Pharmaceutical Research, vol. 7, No. 9, 1990; pp. 902-910.
“Ezetmibe—SCH-58235—1-(4-Fluorophenyl)-3(R)-[3(S)-(4-fluorophenyl)-3-hydroxypropy]-4-(S)-(4hydrocyphenyl)azetidin-2-one”; Drugs of the Future 2000; vol. 25(7), 2000; pp. 679-685.
esp@cenet abstract of DE 101 52 981, May 8, 2003.
esp@cenet abstract of DE 100 64 398, Jun. 27, 2002.
Vaccaro, Wayne D., et al., “Sugar-Substituted 2-Azetidinones As Cholesterol Absorption Inhibitors,” Bioorganic & Medicinal Chemistry Letters 8:35-40 (1998).
Vaccaro, Wayne D., et al., “Sugar-Substituted 2-Azetidinone Cholesterol Absorption Inhibitors: Enhanced Potency by Modification of the Sugar,” Bioorganic & Medicinal Chemistry Letters 8:313-318 (1998).
van Heek, Margaret et. al., “Comparison of the activity and disposition of the novel cholesterol absorption inhibitor, SCH58235, and its glucuronide, SCH60663,” British Journal of Pharmacology 129:1748-1754 (2000).
Zaks, Aleksey, et al., “Enzymatic Glucuronidation of a Novel Cholesterol Absorption Inhibitor, SCH 58235,” Applied Biochemistry and Biotechnology, 73:205-213 (1998).
Schröder, L., “The Peptides,” New York, 1:xxii-xxiii (1965).
Wünsch, “10. Eintelung und Nomenklatur der Peptide und ihrer Derivate,” in Methoden de Organischen Chemie (Houben-Weyl), Stuttgart, Germany, vol. XV, pp. 1-12 (1974).
Flohr Stefanie
Frick Wendelin
Glombik Heiner
Heuer Hubert
Jaehne Gerhard
Berch Mark L.
Sanofi-Aventis Deutschland GmbH
LandOfFree
Acid-group-substituted diphenylazetidinones, process for... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Acid-group-substituted diphenylazetidinones, process for..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Acid-group-substituted diphenylazetidinones, process for... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3893752